BCOP Updates 2026: Beyond Steroids: Updates in Chronic Graft-Versus-Host Disease

Type: Individual•Format: On-demand

Allogeneic hematopoietic cell transplantation (allo-HCT) is a curative therapy for many malignant and non-malignant hematologic disorders for both adult and pediatric patients, but chronic graft-versus-host (cGVHD) disease remains a leading cause of late non-relapse mortality (NRM). Although first-line cGVHD therapy consists of corticosteroids, about half of patients will experience steroid-dependent or steroid-refractory disease, requiring further treatment. There are now 4 FDA-approved agents for the treatment of steroid-dependent or steroid-refractory cGVHD. This session will focus on the four FDA-approved medications in this space, emphasizing their organ system efficacy, place in therapy, mechanism of action, key drug interactions, and adverse event profiles.

BCOP Updates 2026: Beyond Steroids: Updates in Chronic Graft-Versus-Host Disease

Author: C. Brooke Adams, PharmD, BCOP

Learning Objectives

  1. Describe the role of mechanisms of action of ibrutinib, ruxolitinib, belumosudil, and axatilimab in the treatment of steroid refractory chronic graft-versus-host disease (SR GVHD)
  2. Summarize adverse events, organ system response rates, and drug interactions for ibrutinib, ruxolitinib, belumosudil, and axatilimab
  3. Design individualized treatment plans for SR GVHD patients using clinical trial data and patient specific factors
  4. Discuss sequencing principles and the future direction of these therapies for the treatment of cGHVD

Get it now!

Knowledge Course for Pharmacists

Technology requirements: HOPA Learn requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.

acpe-bps-logos

HOPA is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. In order to claim BCOP credit, you must pass the BCOP Post-Test with a 75% or higher.

All CE hours will be transmitted to the CPE Monitor and BPS within 1-2 weeks of course completion.